Incyte does TGF-beta differently
Four months after yielding first-in-human data INCA33890 enters phase 3.
Four months after yielding first-in-human data INCA33890 enters phase 3.
JP Morgan approaches.
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
Mocertatug rezetecan is starting its first western pivotal trials.
PersonGen’s LV009 takes the industry tally of clinical-stage projects to 14.
Nenocorilant features among the latest industry projects newly into phase 1.
Two new PD-(L)1 x VEGF projects have entered the clinic.